New research suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a major medical journal demonstrates that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month after stopping.
"People purchasing such medications must be informed of the potential of quick rebound weight gain when the medication is stopped," warns researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass within about 18 months.
Weighing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Scientists point out that individuals who lose weight through diet and exercise typically experience a more gradual weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Experts suggest the mechanism of the jabs explains the accelerated regain.
These medications mimic a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the system to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Disease?
Health authorities suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the high risk of weight regain, the treatment might need to be long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the jabs describe a sudden resurgence of cravings.
"It was like something activating and I was suddenly extremely hungry," said a patient.
The struggle is compounded if patients have not developed permanent dietary or behavioural changes during treatment.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while these medications are potent tools for weight loss, they are not a magic fix and long-term success hinges on combined behavioural changes.
